RiverPark Advisors LLC Has $4.55 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

RiverPark Advisors LLC boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 94.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,711 shares of the medical equipment provider's stock after acquiring an additional 4,231 shares during the quarter. Intuitive Surgical accounts for 3.2% of RiverPark Advisors LLC's portfolio, making the stock its 6th largest position. RiverPark Advisors LLC's holdings in Intuitive Surgical were worth $4,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Intuitive Surgical by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock valued at $16,813,478,000 after buying an additional 360,591 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Intuitive Surgical by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider's stock worth $4,039,200,000 after purchasing an additional 243,802 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Intuitive Surgical by 1.8% in the 4th quarter. Fisher Asset Management LLC now owns 4,868,869 shares of the medical equipment provider's stock valued at $2,541,356,000 after purchasing an additional 86,488 shares during the period. Norges Bank bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $2,401,493,000. Finally, Invesco Ltd. raised its holdings in shares of Intuitive Surgical by 7.7% in the 4th quarter. Invesco Ltd. now owns 4,148,180 shares of the medical equipment provider's stock valued at $2,165,184,000 after purchasing an additional 295,025 shares during the period. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Price Performance

ISRG stock traded down $2.05 during midday trading on Tuesday, reaching $511.96. 434,841 shares of the stock were exchanged, compared to its average volume of 1,611,592. The stock has a market capitalization of $182.35 billion, a PE ratio of 79.97, a P/E/G ratio of 5.85 and a beta of 1.55. Intuitive Surgical, Inc. has a 52 week low of $367.39 and a 52 week high of $616.00. The company has a fifty day moving average price of $510.03 and a 200 day moving average price of $533.26.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The business had revenue of $2.25 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same quarter in the previous year, the company posted $1.50 EPS. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ISRG shares. Barclays dropped their target price on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Evercore ISI dropped their target price on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a report on Wednesday, April 23rd. Wells Fargo & Company upped their target price on shares of Intuitive Surgical from $630.00 to $687.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Finally, Royal Bank of Canada lowered their price target on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $598.95.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Robert Desantis sold 11,545 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the transaction, the executive vice president now directly owns 5,224 shares of the company's stock, valued at $2,607,925.28. The trade was a 68.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gary Loeb sold 1,700 shares of the business's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $513.18, for a total value of $872,406.00. Following the completion of the transaction, the executive vice president now directly owns 2,245 shares in the company, valued at $1,152,089.10. This represents a 43.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,819 shares of company stock worth $15,937,836. Insiders own 0.70% of the company's stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.